GlySure Introduces Intravascular Glucose Monitoring System
GlySure has launched its continuous intravascular glucose monitoring system in Europe following receipt of CE Mark certification.
The system is indicated for glucose management in adult cardiac surgery patients in intensive care, the UK devicemaker said last week. However, the company has initiated a multicenter trial to support an expanded indication for all intensive care adult patients.
The device has a monitor, fiber optic sensor that measures glucose levels every fifteen minutes, and single-use central venous catheter. It is meant to combat dangerous glucose fluctuations, which pose a significant risk of morbidity or mortality for critically ill patients.
The devicemaker is seeking FDA marketing clearance, and projects the worldwide market share to be $5 billion. — Jason Scott